Results 251 to 260 of about 3,018,484 (379)

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Off-label use of Avastin in Pakistan: Lessons from the 2023 Punjab outbreak. [PDF]

J Public Health Res
Ali SM, Iqbal A, Hamid Z, Rauf SA, Haque MA.   +4 more
europepmc   +1 more source

Off-label medication use in rare pediatric diseases in the United States

, 2021
Albert Fung, Xiaomeng Yue, Patricia R. Wigle, Jeff J. Guo   +3 more
openalex   +2 more sources

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and Considerations. [PDF]

Healthcare (Basel)
Shaw J, Lai C, Bota P, Le A, Andricioaei A, Tran T, Allee T.   +6 more
europepmc   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Off-label use of intravascular lithotripsy in severely calcified carotid stenosis: a case series and literature review. [PDF]

AME Case Rep
Almadani Y, Sen I, Jabeen N, Martino R, Carmody T, Tallarita T.   +5 more
europepmc   +1 more source

A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler [PDF]

, 2005
John R. Hughes, Edgar H. Adams, Mikael Franzon, Matthew Maguire, J Guary   +4 more
openalex   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

ClearDefense Silver Nanoparticles: Characterisation and Safety Assessment for Children's Dental Care Off-label Use. [PDF]

Int Dent J
Harper SL, Mackiewicz MR.
europepmc   +1 more source